Table 1.
Patient demographics.
| TAV | BAV | |||
|---|---|---|---|---|
| NA | TAA | NA | TAA | |
| N (M/F) | 40 (23/16)a | 39 (22/17) | 31 (20/11) | 44 (35/9) |
| Age (year) | 56 ± 16.9 | 67 ± 8.7* | 57 ± 11.2∧ | 56 ± 10.6∧ |
| Diameter (mm) | 32 ± 3.4b | 52 ± 5.8* | 38 ± 3.8c | 51 ± 3.9*∧ |
| AI 1+ | 5.3% | 23.1% | 16.7% | 20.9% |
| 2–3+ | 15.8% | 35.9% | 6.7%∧ | 18.6% |
| 4+ | 5.3% | 20.5% | 26.9% | 11.6% |
| AS Mild | 0% | 0% | 0% | 23.1%∧# |
| Mod | 0% | 0% | 3.3% | 15.4%∧# |
| Severe | 25.0% | 7.7% | 76.7%*∧ | 30.7%∧# |
| HTN | 50.0% | 76.9%* | 61.3% | 70.5% |
| Diabetes | 17.5% | 13.5% | 12.9% | 23.3% |
| Smoking | 47.5% | 43.2% | 43.4% | 45.5% |
| ARB | 0% | 17.9%* | 38.7%*∧ | 9.1%*∧ |
| ACE-inhibitor | 35% | 10.8%* | 12.1% | 37.2%∧# |
| Statins | 27.5% | 53.8%* | 64.5%* | 43.2%* |
Quantitative data are presented as median ± SD.
*, #, and ∧ indicate significance vs. TAV-NA, BAV-NA, and TAV-TAA, respectively and were obtained using a Chi-squared or a Kruskal-Wallis test.
HTN, hypertension; S.D., standard deviation; ARB, angiotensin-receptor blocker; ACE, angiotensin-converting enzyme; AS, aortic stenosis, AI, aortic insufficiency.
a
Sex of one patient was not recorded.
b,c
Calculated from data from 17 and 22 patients, respectively.